This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mulhern, R. K. Articles by Gajjar, A. Search for Related Content PubMed PubMed Citation Articles by Mulhern, R. K. Articles by Gajjar, A. Social Bookmarking                            What's this?

Neurocognitive Consequences of Risk-Adapted Therapy for Childhood Medulloblastoma

Raymond K. Mulhern, Shawna L. Palmer, Thomas E. Merchant, Dana Wallace, Mehmet Kocak, Pim Brouwers, Kevin Krull, Murali Chintagumpala, Robyn Stargatt, David M. Ashley, Vida L. Tyc, Larry Kun, James Boyett, Amar Gajjar

From the Division of Behavioral Medicine, Division of Radiation Oncology, Department of Biostatistics, Division of Neuro-Oncology, Department of Hematology Oncology, St Jude Children's Research Hospital, Memphis TN; Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX; and Royal Children's Hospital, Melbourne, Australia

Address reprint requests to Amar Gajjar, MD, Division of Neuro-Oncology, St Jude Children's Research Hospital, 332 N Lauderdale, Memphis, TN 38105-2794; e-mail: amar.gajjar{at}stjude.org

PURPOSE: This prospective, longitudinal study examined the effects of risk-adapted craniospinal irradiation (CSI) dose and the interactions of dose with age and time from diagnosis on intelligence quotient (IQ) and academic achievement (reading, spelling, and math) among patients treated for medulloblastoma (MB).

PATIENTS AND METHODS: Patients received serial neurocognitive testing spanning from 0 to 6.03 years after diagnosis (median, 3.14 years). The multi-institutional study included 111 patients, who were 3 to 20 years of age at diagnosis (median age, 7.4 years), treated for MB with risk-adapted CSI followed by four cycles of high-dose chemotherapy (cyclophosphamide, cisplatin, and vincristine) with stem-cell support. High-risk patients (HR; n = 37) received CSI to 36 to 39.6 Gy and conformal boost treatment of the primary site to 55.8 to 59.4 Gy. Average-risk patients (AR; n = 74) received CSI to 23.4 Gy and conformal boost treatment of the posterior fossa to 36.0 Gy and primary site to 55.8 Gy.

RESULTS: Multivariate modeling revealed statistically significant declines in mean IQ (–1.59 points/yr; P = .006), reading (–2.95 points/yr; P < .0001), spelling (–2.94 points/yr; P < .0001), and math (–1.87 points/yr; P = .003) scores for the entire group. The effects of risk-adapted radiation therapy on IQ, reading, and spelling were moderated by age, with the greatest rates of decline observed for the HR patients who were younger (< 7 years old) at diagnosis.

CONCLUSION: Young age at diagnosis was the most prominent risk factor for neurocognitive deficits among survivors of MB despite reductions in CSI dosing and efforts to limit the boost volume. Younger patients exhibited substantial problems with the development of reading skills.

Deceased.

This research is supported by Musicians Against Childhood Cancer, the Noyes Foundation, the American Lebanese Syrian Associated Charities, National Cancer Institute grant Nos. R01CA78957 and U01CA81445, and Cancer Center Support grant No. P30CA21765.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Eshelman-Kent, E. Gilger, and M. Gallagher Transitioning Survivors of Central Nervous System Tumors: Challenges for Patients, Families, and Health Care Providers Journal of Pediatric Oncology Nursing, September 1, 2009; 26(5): 280 - 294. [Abstract] [PDF]

				N. Barahmani, S. Carpentieri, X.-N. Li, T. Wang, Y. Cao, L. Howe, L. Kilburn, M. Chintagumpala, C. Lau, and M. F. Okcu Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastoma Neuro Oncology, June 1, 2009; 11(3): 292 - 300. [Abstract] [Full Text] [PDF]

				C. Carrie, J. Grill, D. Figarella-Branger, V. Bernier, L. Padovani, J. L. Habrand, M. Benhassel, M. Mege, M. Mahe, P. Quetin, et al. Online Quality Control, Hyperfractionated Radiotherapy Alone and Reduced Boost Volume for Standard Risk Medulloblastoma: Long-Term Results of MSFOP 98 J. Clin. Oncol., April 10, 2009; 27(11): 1879 - 1883. [Abstract] [Full Text] [PDF]

				S. Rutkowski, N. U. Gerber, K. von Hoff, A. Gnekow, U. Bode, N. Graf, F. Berthold, G. Henze, J. E.A. Wolff, M. Warmuth-Metz, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy Neuro Oncology, April 1, 2009; 11(2): 201 - 210. [Abstract] [Full Text] [PDF]

				M. L. Garre, A. Cama, F. Bagnasco, G. Morana, F. Giangaspero, M. Brisigotti, C. Gambini, M. Forni, A. Rossi, R. Haupt, et al. Medulloblastoma Variants: Age-Dependent Occurrence and Relation to Gorlin Syndrome--A New Clinical Perspective Clin. Cancer Res., April 1, 2009; 15(7): 2463 - 2471. [Abstract] [Full Text] [PDF]

				M. Anclair, E. Hoven, B. Lannering, and K.K. Boman Parental Fears Following Their Child's Brain Tumor Diagnosis and Treatment Journal of Pediatric Oncology Nursing, March 1, 2009; 26(2): 68 - 74. [Abstract] [PDF]

				Y. Cao, C. I. Tsien, P. C. Sundgren, V. Nagesh, D. Normolle, H. Buchtel, L. Junck, and T. S. Lawrence Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for Prediction of Radiation-Induced Neurocognitive Dysfunction Clin. Cancer Res., March 1, 2009; 15(5): 1747 - 1754. [Abstract] [Full Text] [PDF]

				H. M. Conklin, C. Li, X. Xiong, R. J. Ogg, and T. E. Merchant Predicting Change in Academic Abilities After Conformal Radiation Therapy for Localized Ependymoma J. Clin. Oncol., August 20, 2008; 26(24): 3965 - 3970. [Abstract] [Full Text] [PDF]

				K. Yasuda, H. Taguchi, Y. Sawamura, J. Ikeda, H. Aoyama, K. Fujieda, N. Ishii, M. Kashiwamura, Y. Iwasaki, and H. Shirato Low-dose Craniospinal Irradiation and Ifosfamide, Cisplatin and Etoposide for Non-metastatic Embryonal Tumors in the Central Nervous System Jpn. J. Clin. Oncol., July 1, 2008; 38(7): 486 - 492. [Abstract] [Full Text] [PDF]

				N U Gerber, D Zehnder, T J Zuzak, A Poretti, E Boltshauser, and M A Grotzer Outcome in children with brain tumours diagnosed in the first year of life: long-term complications and quality of life Arch. Dis. Child., July 1, 2008; 93(7): 582 - 589. [Abstract] [Full Text] [PDF]

				S. Phipps, S. N. Rai, W.-H. Leung, S. Lensing, and M. Dunavant Cognitive and Academic Consequences of Stem-Cell Transplantation in Children J. Clin. Oncol., April 20, 2008; 26(12): 2027 - 2033. [Abstract] [Full Text] [PDF]

				S. J. Laughton, T. E. Merchant, C. A. Sklar, L. E. Kun, M. Fouladi, A. Broniscer, E. B. Morris, R. P. Sanders, M. J. Krasin, J. Shelso, et al. Endocrine Outcomes for Children With Embryonal Brain Tumors After Risk-Adapted Craniospinal and Conformal Primary-Site Irradiation and High-Dose Chemotherapy With Stem-Cell Rescue on the SJMB-96 Trial J. Clin. Oncol., March 1, 2008; 26(7): 1112 - 1118. [Abstract] [Full Text] [PDF]

				G. T. Armstrong, C. A. Sklar, M. M. Hudson, and L. L. Robison Long-Term Health Status Among Survivors of Childhood Cancer: Does Sex Matter? J. Clin. Oncol., October 1, 2007; 25(28): 4477 - 4489. [Abstract] [Full Text] [PDF]

				S. L. Palmer, W. E. Reddick, and A. Gajjar Understanding the Cognitive Impact on Children Who are Treated for Medulloblastoma J. Pediatr. Psychol., October 1, 2007; 32(9): 1040 - 1049. [Abstract] [Full Text] [PDF]

				K. S. Bull, H. A. Spoudeas, G. Yadegarfar, and C. R. Kennedy Reduction of Health Status 7 Years After Addition of Chemotherapy to Craniospinal Irradiation for Medulloblastoma: A Follow-Up Study in PNET 3 Trial Survivors on Behalf of the CCLG (formerly UKCCSG) J. Clin. Oncol., September 20, 2007; 25(27): 4239 - 4245. [Abstract] [Full Text] [PDF]

				M. M. Geenen, M. C. Cardous-Ubbink, L. C. M. Kremer, C. van den Bos, H. J. H. van der Pal, R. C. Heinen, M. W. M. Jaspers, C. C. E. Koning, F. Oldenburger, N. E. Langeveld, et al. Medical Assessment of Adverse Health Outcomes in Long-term Survivors of Childhood Cancer JAMA, June 27, 2007; 297(24): 2705 - 2715. [Abstract] [Full Text] [PDF]

				R. Vibhakar, G. Foltz, J.-g. Yoon, L. Field, H. Lee, G.-y. Ryu, J. Pierson, B. Davidson, and A. Madan Dickkopf-1 is an epigenetically silenced candidate tumor suppressor gene in medulloblastoma Neuro Oncology, April 1, 2007; 9(2): 135 - 144. [Abstract] [Full Text] [PDF]